Inventor

ABELSON MARK B

US12 patents

⚠️ This page may combine multiple inventors who share the name “ABELSON MARK B”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

ORA INC

4 patents

USD875946SFeb 18, 2020

Apparatus for capturing an image of the eye

ORA INC4 citations66

US12048685B2Jul 30, 2024

Transient receptor potential cation channel subfamily m member 8 (TRPM8) antagonists and methods of use

ORA INC0 citations59

US10603303B2Mar 31, 2020

Transient receptor potential cation channel subfamily M member 8 (TRPM8) antagonists and methods of use

ORA INC1 citations59

US11246483B2Feb 15, 2022

Apparatus for capturing an image of the eye

ORA INC0 citations55

ABELSON MARK B

2 patents

US4981871AJan 1, 1991

Treatment of ocular hypertension with class I calcium channel blocking agents

ABELSON MARK B122 citations95

US9254286B2Feb 9, 2016

Ophthalmic formulations of cetirizine and methods of use

ABELSON MARK B4 citations81

(unassigned)

2 patents

US5435998AJul 25, 1995

Treatment of low-tension glaucoma by topical administration of calcium channel blocking agents

35 citations90

US5431907AJul 11, 1995

Treatment of vascular disorders of the posterior segment of the eye by topical administration of calcium channel blocking agents

30 citations90

INGERMAN AVNER

1 patent

US8664215B2Mar 4, 2014

Ocular allergy treatments with alcaftadine

INGERMAN AVNER6 citations73

COOPER LAB

1 patent

US4315024AFeb 9, 1982

Compositions and method for treating red eye

COOPER LAB11 citations72

OPHTHALMIC RES ASSOCIATES INC

1 patent

US6465506B2Oct 15, 2002

Instillation techniques for ophthalmic agents to enhance treatment effect

OPHTHALMIC RES ASSOCIATES INC2 citations52

VISTAKON PHARMACEUTICALS LLC

1 patent

US10617695B2Apr 14, 2020

Ophthalmic compositions containing alcaftadine

VISTAKON PHARMACEUTICALS LLC0 citations39